-
BI Partners with Sinopharm for Promotion of Sifrol and Pradaxa in China
•
German pharmaceutical major Boehringer Ingelheim (BI) has entered into a partnership with China-based Sinopharm Group Co., Ltd (HKG: 1099), granting the latter the rights to promote Boehringer Ingelheim’s Sifrol (pramipexole) and Pradaxa (dabigatran) in China effective from January 1, 2025. Boehringer Ingelheim will retain ownership and manufacturing responsibilities for both…
-
Boehringer Ingelheim Joins MTM Vision Consortium to Advance Diabetes Retinopathy Research
•
Germany-based pharmaceutical major Boehringer Ingelheim has announced the initiation of a long-term collaboration with the Mary Tyler Moore Vision Initiative (MTM Vision), marking the first time a pharmaceutical company has joined the MTM Vision Consortium. This partnership signifies a significant step in collaborative research aimed at addressing vision-related complications of…
-
Boehringer Ingelheim Partners with Wuhan Union Hospital to Enhance Clinical Research and Development
•
Boehringer Ingelheim, a leading German pharmaceutical company, has entered into a strategic partnership with Wuhan Union Hospital, marking a significant step in the realm of clinical research. This collaboration will extend beyond clinical studies to include academic exchanges, patient education, and talent development, among other areas, in alignment with Boehringer…
-
Boehringer Ingelheim Partners with Broad Institute for Mental Health Treatments
•
Germany-based pharmaceutical major Boehringer Ingelheim has entered into a collaboration agreement with the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard. The joint project aims to address the urgent and unmet needs of individuals living with mental health conditions, with a specific focus on developing…
-
Huahai Pharmaceutical Gets FDA Nod for Generic Empagliflozin and Metformin ANDA
•
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a prominent Chinese pharmaceutical company, has announced the receipt of Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for its generic version of Boehringer Ingelheim’s (BI) empagliflozin and metformin combination therapy. This therapy was originally approved in…
-
Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement
•
Boehringer Ingelheim (BI), a leading German pharmaceutical company, has joined forces with the World Health Organization (WHO) Foundation in a significant pledge to enhance access to quality healthcare services for all, particularly targeting vulnerable groups in the Americas who face a heightened risk of suicide. The commitment involves a substantial…
-
Boehringer Ingelheim Partners with Circle Pharma to Develop First-in-Class Cyclin Inhibitor
•
Boehringer Ingelheim (BI), a leading German pharmaceutical company, has announced a research collaboration and license agreement with Circle Pharma, a US-based firm. This strategic partnership aims to develop a first-in-class cyclin inhibitor, a novel approach that could halt the growth of cancer cells and offer new hope for patients struggling…
-
Boehringer Ingelheim’s Survodutide Earns FDA Breakthrough Therapy Designation for MASH Treatment
•
German pharmaceutical company Boehringer Ingelheim has received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for its drug candidate survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist, for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate or advanced fibrosis (stages 2 or…
-
Boehringer Ingelheim’s Zongertinib Earns Breakthrough Designation in China for HER2-Mutated NSCLC
•
Boehringer Ingelheim, a leading German pharmaceutical company, has received a significant endorsement from China’s Center for Drug Evaluation (CDE) with the breakthrough therapy designation (BTD) for its investigational HER2-targeted tyrosine kinase inhibitor (TKI), zongertinib (BI 1810631). This designation underscores the potential of zongertinib in treating adult patients with HER2-mutated advanced,…
-
Boehringer Ingelheim Initiates Clinical Trial for Novel Anti-Obesity Drug
•
Boehringer Ingelheim (BI), a German pharmaceutical company, has announced the commencement of clinical development for BI 3034701, a potential first-in-class anti-obesity drug. The molecule was originally developed by Denmark-based Gubra A/S (XCSE: GUBRA) and is a long-acting triple-agonist peptide designed to target receptors associated with inducing weight loss, positioning it…
-
Boehringer Ingelheim’s Survodutide Earns Breakthrough Designation for MASH Treatment in China
•
Boehringer Ingelheim (BI), the German pharmaceutical colossus, has declared that it has been granted Breakthrough Therapy Designation (BTD) by China’s Center for Drug Evaluation (CDE) for its experimental drug candidate, survodutide (BI 456906). This designation underscores the drug’s promising therapeutic potential for patients suffering from metabolic dysfunction-associated steatohepatitis (MASH). Derived…
-
Boehringer Ingelheim and Peking University Deepen Partnership with Joint Drug Research Lab
•
Boehringer Ingelheim, a major German pharmaceutical company, has entered into an agreement with China’s Peking University Health Science Center (PKUHSC) to establish a joint laboratory for human use drug research. This long-term partnership builds upon an initial teaching and scientific research cooperation memorandum of understanding signed back in 2014. Since…
-
Amoy Diagnostics Teams Up with Boehringer Ingelheim for CDx Developmen
•
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a prominent player in China’s tumor precision medicine space, has entered into a strategic collaboration with Germany’s Boehringer Ingelheim to advance the development of companion diagnostics (CDx). The partnership is aimed at identifying non-small cell lung cancer (NSCLC) patients who are most likely…
-
Boehringer Ingelheim’s Anti-Sema3A BI 764524 Shows Promise in Diabetic Macular Ischemia Trial
•
Boehringer Ingelheim (BI) has announced the publication of results from a Phase I/IIa clinical trial for its anti-Sema3A antibody candidate, BI 764524, used in the treatment of diabetic macular ischemia (DMI), a serious complication of diabetic retinopathy (DR) that can result in blindness. The trial successfully met its primary safety…
-
Boehringer Ingelheim Surpasses Bayer in Pharma Sales with EUR 20.8 Billion in 2023
•
Boehringer Ingelheim, a major German pharmaceutical company, has released its financial report for 2023, announcing human pharma sales of EUR 20.8 billion (USD 22.1 billion), marking a 10.3% year-on-year (YOY) increase, excluding currency effects. Additionally, animal health sales rose by 6.9% YOY to EUR 4.7 billion (USD 4.9 billion), leading…
-
Boehringer Ingelheim’s Shanghai Unit Secures EMA and FDA Approval for Biopharmaceutical Supply
•
Germany-based Boehringer Ingelheim has announced that its Shanghai-based Contract Manufacturing Organization (CMO), Boehringer Ingelheim Biopharmaceuticals China (BioChina), has successfully passed pre-approval inspections conducted by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). This approval allows its customer to supply biopharmaceuticals to the EU and…
-
Sino Biopharmaceutical Partners with Boehringer Ingelheim to Bring Innovative Cancer Therapies to China
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a strategic partnership with Germany’s Boehringer Ingelheim (BI) to introduce BI’s innovative cancer therapies to the mainland China market. Under the terms of the agreement, Sino Bio will provide support for the co-development and co-commercialization of several clinical-stage drugs, including brigimadlin, zongertinib, and…
-
Boehringer Ingelheim to Shut Down Consanas Rehabilitation Unit in China Amid Disappointing Performance
•
Boehringer Ingelheim (BI), the Germany-based pharmaceutical firm, is set to close its Consanas Rehabilitation stroke care unit in China, despite ongoing efforts to develop innovative treatments for the disease. This move follows disappointing performance metrics, with only 11.5% of stroke patients in China receiving rehabilitative treatment within a week and…
-
Boehringer Ingelheim Partners with Sosei Group to Develop GPR52 Agonists for Schizophrenia
•
Boehringer Ingelheim (BI), headquartered in Germany, has entered into a global collaboration and exclusive option-to-license agreement with Sosei Group Corporation (TSE: 4565), a Japanese firm. This strategic partnership aims to develop and commercialize Sosei Heptares’ portfolio of first-in-class GPR52 agonists, targeting a novel G protein-coupled receptor (GPCR) to address the…
-
Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy
•
Germany’s Boehringer Ingelheim (BI), US-based Johnson & Johnson (J&J; NYSE: JNJ), and Denmark’s major Novo Nordisk’s controlling shareholder, Novo Holdings, have participated in a EUR 30 million (USD 32.6 million) Series A financing round for Sweden-based Asgard Therapeutics. Asgard Therapeutics specializes in in in vivo cell reprogramming for cancer immunotherapy,…
-
Boehringer Ingelheim’s Spevigo Receives NMPA Approval for GPP Treatment in China
•
German pharmaceutical giant Boehringer Ingelheim (BI) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its biologic drug Spevigo (spesolimab) subcutaneous injection. The drug is indicated for reducing the incidence of generalized pustular psoriasis (GPP) in adolescents aged 12 and above weighing at…
-
Boehringer Ingelheim Expands Greek Facility to Boost Production of Jardiance and Other Medications
•
Boehringer Ingelheim (BI), headquartered in Germany, has commenced the expansion of its manufacturing facility in Greece as part of a strategic plan initiated in 2020 to enhance production capacity. This EUR 120 million investment aims to bolster the supply of medications to the US market, with a particular focus on…
-
Boehringer Ingelheim Teams Up with 3T Biosciences for Next-Gen T-Cell Cancer Therapies
•
German pharmaceutical leader Boehringer Ingelheim (BI) has entered into a new agreement with U.S.-based 3T Biosciences to advance next-generation T-cell-based immuno-oncology therapies. BI will contribute its proprietary patient-derived T-cell receptor (TCR) data to help identify binding antigens using 3T’s discovery platform. Under the terms, BI will provide an undisclosed upfront…
-
Boehringer Ingelheim Partners with Suzhou Ribo Life Science to Develop siRNA Therapies for NASH/MASH
•
Boehringer Ingelheim (BI), a Germany-headquartered pharmaceutical company, has entered into a collaboration agreement with Suzhou Ribo Life Science Co., Ltd, a Chinese biotechnology firm, to co-develop small interfering RNA (siRNA) drugs for the treatment of non-alcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). This strategic partnership aims to leverage Ribo’s proprietary RIBO-GalSTAR…
-
Boehringer Ingelheim Partners with Ten63 Therapeutics to Discover Novel Drug Molecules
•
Boehringer Ingelheim (BI), based in Germany, has announced a collaboration with U.S. drug discovery firm Ten63 Therapeutics, aimed at identifying multiple novel molecules across various indications with significant unmet medical needs. Financial details of the partnership have not been disclosed. This collaboration will leverage BI’s extensive pre-clinical and clinical expertise…
-
Boehringer Ingelheim Partners with Shanghai Handu Pharma to Enhance Oral Medication Delivery
•
Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Shanghai Handu Pharmaceutical Technology Co., Ltd, a China-based company previously established as a wholly foreign-owned enterprise (WFOE) by Hong Kong WD Pharmaceutical Co., Ltd. The financial details of the agreement have not been disclosed. This collaboration aims…
-
Boehringer Ingelheim Partners with Phenomic AI to Target Stroma-Rich Cancers
•
Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Canada’s Phenomic AI to leverage the latter’s single-cell transcriptomics platform for the discovery of drug targets in stroma-rich cancers, including colorectal and pancreatic tumors. In return for the option to license the identified targets and secure development…
-
Boehringer Ingelheim and Eli Lilly’s Jardiance Receives NMPA Approval for CKD Treatment
•
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced that their SGLT2 inhibitor, Jardiance (empagliflozin), has received marketing approval from the National Medical Products Administration (NMPA) for the treatment of adult chronic kidney disease (CKD). This development expands the drug’s therapeutic applications in China. EMPA-KIDNEY Study Outcomes The approval…
-
Boehringer Ingelheim and Eli Lilly Secure NMPA Approval for Jardiance in Chronic Kidney Disease
•
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced the receipt of marketing approval from the National Medical Products Administration (NMPA) for their SGLT2 inhibitor Jardiance (empagliflozin) aimed at treating adult chronic kidney disease (CKD). This pivotal approval marks a significant advancement in the management of CKD, further establishing…
-
Boehringer Ingelheim Acquires T3 Pharmaceuticals to Boost Immuno-Oncology Portfolio
•
Germany’s Boehringer Ingelheim has announced the purchase of Switzerland-based biotechnology firm T3 Pharmaceuticals this week, in a strategic move to expand its immuno-oncology pipeline. The transaction is valued at up to CHF 450 million (USD 510 million), highlighting Boehringer Ingelheim’s commitment to advancing cancer treatments. T3 Pharmaceuticals’ Innovative Approach to…
-
Boehringer Ingelheim and Scottish Enterprise Co-Lead GBP 4.3M Seed Funding for Glox Therapeutics
•
Germany’s Boehringer Ingelheim, in collaboration with Scotland’s national economic development agency Scottish Enterprise, has co-led a GBP 4.3 million (USD 5.3 million) seed funding round for Scotland-based biotechnology company Glox Therapeutics. The investment will enable Glox to establish new laboratories and expand its team, bolstering its mission to develop precision…
-
Boehringer Ingelheim’s Aldosterone Synthase Inhibitor BI 690517 Shows Promise in CKD Phase II Trial
•
Germany-based Boehringer Ingelheim (BI) has published the results of a Phase II trial for its aldosterone synthase inhibitor (ASi) BI 690517, used alone or in combination with the antidiabetic Jardiance (empagliflozin), in patients with chronic kidney disease (CKD), with or without type 2 diabetes (T2D). The trial aimed to evaluate…
-
Boehringer Ingelheim Appoints Mohammed Tawil as New CEO for Greater China Region
•
Germany’s Boehringer Ingelheim (BI) has announced a leadership transition within its Greater China region, which includes mainland China, Hong Kong, and Taiwan. Dr. Pavol Dobrocky will be succeeded by Mohammed Tawil as the president and chief executive officer (CEO). Mohammed Tawil’s Background and ExperienceMohammed Tawil currently serves as the president,…
-
Boehringer Ingelheim’s Vitiligo Drug EI-001 Approved for Clinical Trials by NMPA
•
Germany’s Boehringer Ingelheim (BI) has announced that the National Medical Products Administration (NMPA) has approved an Investigational New Drug (IND) filing for EI-001, a Category 1 vitiligo drug co-developed by Elixiron Immunotherapeutics. This approval marks a significant milestone in the development of new treatment options for vitiligo, a condition that…
-
Boehringer Ingelheim and Eli Lilly’s Jardiance Wins FDA Approval for CKD Prevention
•
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have received regulatory approval from the US Food and Drug Administration (FDA) for their SGLT2 inhibitor, Jardiance (empagliflozin), marking a significant advancement in the treatment of chronic kidney disease (CKD). The drug is now approved for the prevention of kidney function decline,…
-
Boehringer Ingelheim Gets NMPA Approval for Brigimadlin Safety and Efficacy Study in China
•
Germany-based Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct the Brightline-2 study in China. The study will assess the safety and efficacy of the company’s MDM2-p53 antagonist, brigimadlin (BI 907828), in patients with locally advanced/metastatic, MDM2 amplification, TP53 wild-type…
-
EMA and FDA Review AbbVie’s Skyrizi for Ulcerative Colitis Indication Extension
•
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have accepted for review indication extension filings for AbbVie’s (NYSE: ABBV) interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) for the treatment of moderately to severely active ulcerative colitis (UC). This development marks a further expansion of Skyrizi’s potential applications…
